News
HRI Statement on conclusion of Frass et al. 2020 investigation
30 September 2024
In 2022, serious allegations were made against a research team led by Prof Michael Frass, calling into question the veracity of their stu...
More
Hot off the press
Scientific guidelines for preclinical research on potentised preparations manufactured according to current pharmacopoeias—the PrePoP guidelines Open Access
Tournier AL, Bonamin LV, Buchheim-Schmidt S et al.
J Integr Med, 2024; S2095-4964(24): 00341-8
Full text
Hear from the experts
N-of-1 trials and integrative oncology | Dr Jean-Lionel Bagot & Dr Ingrid Theunissen
Oncologists Dr Jean-Lionel Bagot and Dr Ingrid Theunissen discuss the work they presented at HRI London 2023, which explores the concept of N-of-1 trials in the context of homeopathy and integrative oncology.
Evidence base highlight
Zincum Metallicum, a homeopathic drug, alleviates Zn-induced toxic effects and promotes plant growth and antioxidant capacity in Lepidium sativum L
Boudali, G, Ghnaya, T, Ben-Abdallah, S et al.
Environ Sci Pollut Res, 2022. 29, 33872–33884
Abstract
News
The highest level of scientific evidence supports cost-effectiveness of homeopathy – a finding that is unchanged by a recent paper by Leemhuis & Seifert
We read with interest a new paper by Leemhuis & Seifert published in March 2024, titled, “Prescriptions of homeopathic remedies at the expense of the German statutory health insurance from 1985 to 2021: scientific, legal and pharmacoeconomic analysis”. However, regrettably, this study fails to meet basic scientific standards for a meaningful economic evaluation and, as such, adds nothing of value to the evidence base on this topic. More
